Deep TMS technology has created a new era in brain disorder treatment. A unique non-drug treatment based on magnetic brain stimulation, it brings substantial improvement without causing systemic or long-term side effects such as those caused by antidepressants.
Brainsway Deep TMS has been proven to be effective for patients with severe, presistent depression who tried several medications without success.
Brainsway’s unique technology is based on patents registered by the National Institute of Health (NIH) and by the company. It has received an FDA clearance for treating depression and a variety of additional indications from health institutions worldwide such as the CE and ANVISA.
For more information please visit www.brainsway.com
Brainsway Deep TMS has been proven to be effective for patients with severe, presistent depression who tried several medications without success.
Brainsway’s unique technology is based on patents registered by the National Institute of Health (NIH) and by the company. It has received an FDA clearance for treating depression and a variety of additional indications from health institutions worldwide such as the CE and ANVISA.
For more information please visit www.brainsway.com
Location: United States, Massachusetts, Burlington
Employees: 51-200
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Shavit Cap... | shavitcapi... |
Mentions in press and media 16
| Date | Title | Description |
| 31.03.2026 | Neurolief Secures Major Funding for At-Home Depression Therapy | Neurolief secures $6M from BrainsWay. FDA approved its ProlivRx system. This brain neuromodulation therapy treats major depressive disorder at home. It targets patients resistant to antidepressants. The investment fuels U.S. rollout. It vas... |
| 30.03.2026 | Neurolief Raises Additional $6M Investment | Neurolief Proliv Rx Neurolief, a Coral Springs, FL-based medical technology company developing neuromodulation therapies for mental health conditions, raised a $6M investment from BrainsWay Ltd. The news followed the FDA Premarket Approval ... |
| 30.03.2026 | Neurolief: $6 Million Investment Raised For FDA-Approved At-Home Depression Neuromodulation Therapy | Neurolief, a neuroscience-driven medical technology company focused on non-invasive neuromodulation therapies, has secured a $6 million milestone-based investment from BrainsWay following FDA Premarket Approval of its ProlivRx system. The f... |
| 02.07.2024 | Patients on these antidepressants were more likely to gain weight, study says | New research is comparing the weight changes of patients taking different types of antidepressants, one of the most commonly prescribed medications in the United States. The study, published on Tuesday in the Annals of Internal Medicine, an... |
| 06.03.2024 | BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights | - |
| 21.03.2023 | Spiritual Awakening Arrives as Masses Attend Asbury Campus Revival and Jesus Revolution Movie | Australian College Students Christen Prophetic Book Prior to Revival This book is more than a good read; it's an operating manual for success. We should be teaching this to our young adults and future leaders” — David CaspilloSILICON VALLEY... |
| 16.09.2022 | Cigna extends coverage for Brainsway’s brain stimulation device to treat OCD | Obsessive-Compulsive Disorder (OCD) has been ranked by the World Health Organization as one of the top 10 most debilitating medical conditions in terms of loss of income and decreased quality of life. The condition is a complex one that pre... |
| 26.08.2022 | Leaders Say Surveillance Of ‘Quiet Quitters’ Doesn’t Work But 3 Steps Do | Does monitoring employees improve engagement and productivity or undermine it? getty |
| 01.03.2021 | BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters’ Option to Purchase Additional American Depositary ... | CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the closing... |
| 29.08.2015 | From Practice Fusion’s future to CVS teaming up with telemedicine competitors: 5 must-read stories from MedCity News this week | 1. Practice Fusion’s future seems uncertain despite Theranos deal If anyone knows what’s really going on with Practice Fusion, please raise your hand. Earlier this month, the San Francisco vendor of a free, cloud-based electronic health rec... |
Show more